SI-Bone Inc (DE:2K3)
FRANKFURT:2K3
2K3 Stock Chart & Stats
€11.50
€0.10(0.75%)
At close: 4:00 PM EST
€11.50
€0.10(0.75%)
Day’s Range― - ―
52-Week Range€9.65 - €17.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€581.92M
Enterprise Value€599.14M
Total Cash (Recent Filing)€144.68M
Total Debt (Recent Filing)€7.35M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 10, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding44,349,280
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)4.83
Price to Sales (P/S)4.27
P/FCF Ratio-94.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.78Price Target Upside71.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.43
Revenue Forecast (FY)€195.98M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~79–80% gross margins indicate durable unit economics for SI-Bone's implant systems. High product-level margins provide pricing flexibility, support reinvestment in R&D and commercial expansion, and allow incremental revenue to flow to operating leverage as volumes scale.
Low Leverage And Liquidity RunwayVery low leverage and a large cash balance provide financial flexibility to fund launches, R&D and commercial buildouts without immediate refinancing. This reduces solvency risk and preserves strategic optionality during multi-quarter ramp and product commercialization phases.
Expanding Physician Base & Territory ProductivityConsistent, multi-year physician adoption and rising revenue per territory show durable commercial traction and scalable sales productivity. A growing, engaged surgeon base supports repeat per-procedure implant demand and helps convert new territories into sustained revenue streams over quarters.
Bears Say
Negative Free Cash FlowAlthough operating cash flow turned positive, persistent negative free cash flow reflects ongoing investment and working-capital needs. Continued cash consumption delays self-funded growth and may require sustained cash reserves or financing until break-even free cash flow is achieved.
Execution And Partnership Ramp RiskGrowth materially depends on a phased third-party rollout and internal onboarding. Delays in training, hospital approvals, or distributor adoption can push revenue recognition and compress expected operating leverage, making multi-quarter growth outcomes more binary and execution-sensitive.
ASP Pressure From Mix ShiftsA structural shift toward procedures that use fewer implants or lower-priced SKUs can depress average selling price. Even with volume growth, mix-driven ASP erosion could cap revenue per procedure and limit gross-profit expansion, constraining long-term margin improvement.
SI-Bone News
2K3 FAQ
What was SI-Bone Inc’s price range in the past 12 months?
SI-Bone Inc lowest stock price was €9.65 and its highest was €17.90 in the past 12 months.
What is SI-Bone Inc’s market cap?
SI-Bone Inc’s market cap is €581.92M.
When is SI-Bone Inc’s upcoming earnings report date?
SI-Bone Inc’s upcoming earnings report date is Aug 10, 2026 which is in 64 days.
How were SI-Bone Inc’s earnings last quarter?
SI-Bone Inc released its earnings results on May 11, 2026. The company reported -€0.085 earnings per share for the quarter, beating the consensus estimate of -€0.16 by €0.075.
Is SI-Bone Inc overvalued?
According to Wall Street analysts SI-Bone Inc’s price is currently Undervalued.
Does SI-Bone Inc pay dividends?
SI-Bone Inc does not currently pay dividends.
What is SI-Bone Inc’s EPS estimate?
SI-Bone Inc’s EPS estimate is -0.13.
How many shares outstanding does SI-Bone Inc have?
SI-Bone Inc has 44,349,280 shares outstanding.
What happened to SI-Bone Inc’s price movement after its last earnings report?
SI-Bone Inc reported an EPS of -€0.085 in its last earnings report, beating expectations of -€0.16. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of SI-Bone Inc?
Currently, no hedge funds are holding shares in DE:2K3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SI-Bone Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€19.78 (71.96% Upside)
€19.78 (71.96% Upside)
Blogger Sentiment
Bullish
DE:2K3 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €416.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.16%
12-Months-Change
Fundamentals
Return on Equity
-9.56%
Trailing 12-Months
Asset Growth
6.79%
Trailing 12-Months
Company Description
SI-Bone Inc
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
2K3 Company Deck
2K3 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and financial momentum: double-digit top-line growth, industry-leading gross margins (~79.8%), improving profitability (Adjusted EBITDA up >440%), record physician engagement, multiple product launches, and a meaningful potential reimbursement tailwind from proposed CMS DRG changes. These positives are balanced by remaining GAAP net losses, negative free cash flow (though improved), near-term cash flow variability from HQ buildout and CapEx, and execution/timing risks around partner rollouts and ASP mix pressure. On balance, the strength in growth, margins, guidance raise, product pipeline, and reimbursement outlook outweigh the execution and timing headwinds.View all DE:2K3 earnings summaries2K3 Stock 12 Month Forecast
Average Price Target
€19.78
▲(71.96% Upside)
Technical Analysis
Options Prices
Currently, No data available
---